Hexvix (Hexaminolevulinate)

Hexvix is indicated for the detection of non‑muscle invasive bladder cancer during cystoscopic examination. It assists clinicians in identifying suspicious lesions that may be missed under white‑light inspection.

• Enhances visualization of carcinoma in situ and flat lesions.
• Improves detection of small papillary tumors.
• Supports targeted biopsy or resection of fluorescent areas.
• Can be used in conjunction with standard white‑light cystoscopy.
• May aid in mapping tumor extent for treatment planning.
• Facilitates documentation of lesion location for follow‑up assessments.
• May improve overall diagnostic yield when combined with adjunct imaging.

• Hexvix contains hexaminolevulinate, a prodrug that preferentially accumulates in malignant urothelial cells. Inside these cells, enzymatic conversion produces protoporphyrin IX, a fluorescent porphyrin. When the bladder is illuminated with blue light (approximately 405 nm), protoporphyrin IX emits red‑orange fluorescence, highlighting cancerous tissue while normal urothelium remains non‑fluorescent. This selective fluorescence enables clinicians to differentiate malignant from benign areas during cystoscopy effectively.

Adverse reactions to Hexvix are generally related to the intravesical administration and the photosensitizing properties of the agent.

Common

• Mild bladder discomfort or urgency during or shortly after instillation.
• Transient hematuria or pink urine discoloration.
• Temporary urinary frequency or dysuria.
• Mild irritation of the urethral mucosa.
• Slight burning sensation during bladder filling.
• Mild suprapubic pressure.

Serious

• Severe allergic reaction such as anaphylaxis.
• Prolonged or intense bladder pain lasting more than 24 hours.
• Persistent hematuria requiring medical evaluation.
• Development of photosensitivity reactions in surrounding tissues.
• Delayed urinary retention needing catheterization.
• Unexplained fever or systemic signs of infection.

These events are typically identified during the post‑procedure observation period.

Before using Hexvix, clinicians should assess patient suitability and follow specific safety measures to minimize risks associated with the intravesical photosensitizer.

• Confirm absence of active urinary tract infection prior to instillation.
• Ensure bladder capacity is adequate to hold the recommended volume.
• Avoid use in patients with known hypersensitivity to hexaminolevulinate or related compounds.
• Withhold the product if recent bladder surgery or instrumentation has occurred within the past 24 hours.
• Monitor patients for at least 30 minutes after administration for immediate adverse reactions.
• Advise patients to report any prolonged pain, bleeding, or urinary changes promptly.
• Document fluorescence findings and any adverse events in the medical record.

Hexvix is administered directly into the bladder, and systemic drug interactions are uncommon; however, certain agents and conditions may affect its safety or fluorescence performance.

Avoid

• Concurrent use of other intravesical photosensitizers or agents that cause bladder irritation.
• Administration immediately after intravesical chemotherapy or immunotherapy without appropriate interval.

Use with caution

• Patients receiving systemic photosensitizing drugs (e.g., porfimer sodium) should be monitored for additive photosensitivity.
• Anticoagulant therapy may increase the risk of hematuria after instillation.
• Use caution in individuals with severe renal impairment, as altered clearance may affect bladder exposure.
• Recent bladder instrumentation may potentiate mucosal irritation.